Experimental Immunology Group, Department of Immunopharmacology, Novo Nordisk A/S, Måløv, Denmark.
Clin Exp Immunol. 2013 Feb;171(2):220-30. doi: 10.1111/cei.12005.
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)-immunoglobulin (Ig) has immunosuppressive properties both in vivo and in vitro, but much is still unknown about the mechanisms by which CTLA-4-Ig exerts its immunosuppressive activities in vivo. The aim of this study was to investigate the effect of CTLA-4-Ig in a mouse model of contact hypersensitivity (CHS). The inflammatory response in the presence or absence of CTLA-4-Ig was evaluated by measuring the increase in ear thickness in sensitized animals after challenge. We observed a dose-dependent suppression of the ear swelling in both dinitrofluorobenzene (DNFB)- and oxazolone-induced CHS. The suppressive effect was still present 3 weeks after administration, even in the absence of circulating levels of CTLA-4-Ig. It was further shown that CTLA-4-Ig inhibits activation of T cells in the draining lymph node after sensitization and affects the maturation level of both dendritic cells and B cells. Furthermore, CTLA-4-Ig reduces infiltration of activated CD8(+) T cells into the inflamed ear tissue and suppresses both local and systemic inflammation, as illustrated by reduced expression of cytokines and chemokines in the inflamed ear and a reduced level of acute-phase proteins in circulation. Finally, our results suggest that CTLA-4-Ig has a mainly immunosuppressive effect during the sensitization phase. We conclude that CTLA-4-Ig induces long-term immunosuppression of both DNFB- and oxazolone-induced inflammation and our data are the first to compare the effect of this compound in both DNFB- and oxazolone-induced CHS and to show that CTLA-4-Ig exerts an immunosuppressive effect on both local and systemic inflammatory mediators which is mediated principally during the sensitization phase.
细胞毒性 T 淋巴细胞相关抗原-4(CTLA-4)-免疫球蛋白(Ig)在体内和体外均具有免疫抑制特性,但关于 CTLA-4-Ig 在体内发挥免疫抑制活性的机制仍知之甚少。本研究旨在探讨 CTLA-4-Ig 在接触性超敏反应(CHS)小鼠模型中的作用。通过测量致敏动物在挑战后耳朵厚度的增加来评估存在或不存在 CTLA-4-Ig 时的炎症反应。我们观察到二硝基氟苯(DNFB)和恶唑酮诱导的 CHS 中均存在剂量依赖性的耳部肿胀抑制作用。给药 3 周后,即使没有循环 CTLA-4-Ig 水平,抑制作用仍然存在。进一步表明 CTLA-4-Ig 抑制致敏后引流淋巴结中 T 细胞的活化,并影响树突状细胞和 B 细胞的成熟水平。此外,CTLA-4-Ig 减少激活的 CD8(+)T 细胞浸润到发炎的耳部组织,并抑制局部和全身炎症,如在发炎的耳部中减少细胞因子和趋化因子的表达以及循环中急性期蛋白水平降低所示。最后,我们的结果表明 CTLA-4-Ig 在致敏阶段具有主要的免疫抑制作用。我们得出结论,CTLA-4-Ig 诱导二硝基氟苯和恶唑酮诱导的炎症的长期免疫抑制,并且我们的数据首次比较了该化合物在二硝基氟苯和恶唑酮诱导的 CHS 中的作用,并表明 CTLA-4-Ig 对局部和全身炎症介质均具有免疫抑制作用,这主要是在致敏阶段介导的。